Literature DB >> 24037606

Causes of certifications for severe sight impairment (blind) and sight impairment (partial sight) in children in England and Wales.

D Mitry1, C Bunce, R Wormald, S Leamon, P Simkiss, P Cumberland, J Rahi, R Bowman.   

Abstract

AIM: To explore and describe trends in the principal disorders/conditions ('cause') for severe sight impairment (SSI) (blind) and sight impairment (SI) (partial sight) certification in children in England and Wales since 1999.
METHODS: We obtained certification data for SI and SSI from a national database for all individuals aged 16 years or less at the time of certification in England and Wales for the years 1999/2000 and for the years 2007/2008-2009/2010.
RESULTS: In total, there were 861 certifications in the year 1999/2000, rising to 1040 certifications in 2009/2010. The commonest single causes of SSI certification in 1999/2000 were cerebral visual impairment (23.2%) and optic nerve disorders (23.2%). The commonest single causes of SI certification in the same year comprised nystagmus (16.7%) and optic nerve disorders (15.5%). Cerebral visual impairment was the commonest single cause of SSI in children in England and Wales annually between 2007/2008 and 2009/2010 accounting for 21%-31% of certifications. The commonest causes of SI certification in 2009/2010 were congenital globe anomalies (18.4%) and retinal dystrophy (16.6%). The proportion of SI and SSI due to optic nerve disorders has decreased since 1999/2000.
CONCLUSIONS: Our findings suggest that in England and Wales, cerebral visual impairment is now the commonest cause of paediatric SSI certification and hereditary retinal dystrophy and congenital globe anomalies are the commonest causes of SI certification.

Entities:  

Keywords:  Child health (paediatrics); Epidemiology; Vision

Mesh:

Year:  2013        PMID: 24037606     DOI: 10.1136/bjophthalmol-2013-303578

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

Review 1.  [Optic nerve hypoplasia and septo-optic dysplasia].

Authors:  R Lohmüller; A-S Gangloff; F Wenzel; W A Lagrèze
Journal:  Ophthalmologe       Date:  2017-08       Impact factor: 1.059

Review 2.  Optical reading aids for children and young people with low vision.

Authors:  Lucy Barker; Rachel Thomas; Gary Rubin; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2015-03-04

3.  [Ophthalmological rehabilitation of visually impaired children].

Authors:  E K Altpeter; N X Nguyen
Journal:  Ophthalmologe       Date:  2017-07       Impact factor: 1.059

4.  Monocular and binocular visual impairment in the UK Biobank study: prevalence, associations and diagnoses.

Authors:  Martin McKibbin; Tracey M Farragher; Darren Shickle
Journal:  BMJ Open Ophthalmol       Date:  2018-01-31

5.  Pleiotropic effect of a novel mutation in GCNT2 causing congenital cataract and a rare adult i blood group phenotype.

Authors:  Sek-Shir Cheong; Sarah Hull; Benjamin Jones; Ravinder Chana; Nicole Thornton; Vincent Plagnol; Anthony T Moore; Alison J Hardcastle
Journal:  Hum Genome Var       Date:  2017-02-16

6.  Is there evidence that the yearly numbers of children newly certified with sight impairment in England and Wales has increased between 1999/2000 and 2014/2015? A cross-sectional study.

Authors:  Catey Bunce; Antra Zekite; Richard Wormald; Richard Bowman
Journal:  BMJ Open       Date:  2017-09-01       Impact factor: 2.692

7.  Causes of visual impairment in applications for blindness certificates in a tertiary center of Bihar and its role in health planning.

Authors:  Anita Ambastha; Rakhi Kusumesh; Shalini Sinha; Bibhuti P Sinha; Gyan Bhasker
Journal:  Indian J Ophthalmol       Date:  2019-02       Impact factor: 1.848

8.  Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia.

Authors:  Rachael C Heath Jeffery; Syed Aqif Mukhtar; Ian L McAllister; William H Morgan; David A Mackey; Fred K Chen
Journal:  Ophthalmic Genet       Date:  2021-05-03       Impact factor: 1.803

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.